OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants
Venice Servellita, Abdullah M. Syed, Mary Kate Morris, et al.
Cell (2022) Vol. 185, Iss. 9, pp. 1539-1548.e5
Open Access | Times Cited: 159
Venice Servellita, Abdullah M. Syed, Mary Kate Morris, et al.
Cell (2022) Vol. 185, Iss. 9, pp. 1539-1548.e5
Open Access | Times Cited: 159
Showing 1-25 of 159 citing articles:
Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
Khadija Khan, Farina Karim, Yashica Ganga, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 156
Khadija Khan, Farina Karim, Yashica Ganga, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 156
Recall of preexisting cross-reactive B cell memory after Omicron BA.1 breakthrough infection
Chengzi I. Kaku, Alan Bergeron, Clas Ahlm, et al.
Science Immunology (2022) Vol. 7, Iss. 73
Open Access | Times Cited: 116
Chengzi I. Kaku, Alan Bergeron, Clas Ahlm, et al.
Science Immunology (2022) Vol. 7, Iss. 73
Open Access | Times Cited: 116
Omicron sub-lineages BA.4/BA.5 escape BA.1 infection elicited neutralizing immunity
Khadija Khan, Farina Karim, Yashica Ganga, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 84
Khadija Khan, Farina Karim, Yashica Ganga, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 84
Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity
Muriel Aguilar-Bretones, Ron A. M. Fouchier, Marion Koopmans, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 1
Open Access | Times Cited: 81
Muriel Aguilar-Bretones, Ron A. M. Fouchier, Marion Koopmans, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 1
Open Access | Times Cited: 81
Omicron infection enhances Delta antibody immunity in vaccinated persons
Khadija Khan, Farina Karim, Sandile Cele, et al.
Nature (2022) Vol. 607, Iss. 7918, pp. 356-359
Open Access | Times Cited: 74
Khadija Khan, Farina Karim, Sandile Cele, et al.
Nature (2022) Vol. 607, Iss. 7918, pp. 356-359
Open Access | Times Cited: 74
Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
Alexander Muik, Bonny Gaby Lui, Maren Bacher, et al.
Science Immunology (2022) Vol. 7, Iss. 77
Open Access | Times Cited: 68
Alexander Muik, Bonny Gaby Lui, Maren Bacher, et al.
Science Immunology (2022) Vol. 7, Iss. 77
Open Access | Times Cited: 68
Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
Evropi Amanatidou, Anna Gkiouliava, Eva Pella, et al.
Metabolism Open (2022) Vol. 14, pp. 100180-100180
Open Access | Times Cited: 67
Evropi Amanatidou, Anna Gkiouliava, Eva Pella, et al.
Metabolism Open (2022) Vol. 14, pp. 100180-100180
Open Access | Times Cited: 67
Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population
Jia Wei, Nicole Stoesser, Philippa C. Matthews, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 26
Jia Wei, Nicole Stoesser, Philippa C. Matthews, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 26
Recent developments in the immunopathology of COVID ‐19
Huanping Zhang, Yuanli Sun, Yanfen Wang, et al.
Allergy (2022) Vol. 78, Iss. 2, pp. 369-388
Open Access | Times Cited: 65
Huanping Zhang, Yuanli Sun, Yanfen Wang, et al.
Allergy (2022) Vol. 78, Iss. 2, pp. 369-388
Open Access | Times Cited: 65
SARS-CoV-2 hybrid immunity: silver bullet or silver lining?
Rahul Suryawanshi, Melanie Ott
Nature reviews. Immunology (2022) Vol. 22, Iss. 10, pp. 591-592
Open Access | Times Cited: 63
Rahul Suryawanshi, Melanie Ott
Nature reviews. Immunology (2022) Vol. 22, Iss. 10, pp. 591-592
Open Access | Times Cited: 63
Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans
Zijun Wang, Pengcheng Zhou, Frauke Muecksch, et al.
The Journal of Experimental Medicine (2022) Vol. 219, Iss. 12
Open Access | Times Cited: 49
Zijun Wang, Pengcheng Zhou, Frauke Muecksch, et al.
The Journal of Experimental Medicine (2022) Vol. 219, Iss. 12
Open Access | Times Cited: 49
Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies
Maher A. Sughayer, Lina Souan, Maha M. Abu Alhowr, et al.
Vaccine (2022) Vol. 40, Iss. 20, pp. 2841-2847
Open Access | Times Cited: 44
Maher A. Sughayer, Lina Souan, Maha M. Abu Alhowr, et al.
Vaccine (2022) Vol. 40, Iss. 20, pp. 2841-2847
Open Access | Times Cited: 44
SARS-CoV-2 Omicron BA.1 and BA.2 are attenuated in rhesus macaques as compared to Delta
Neeltje van Doremalen, Manmeet Singh, Taylor A. Saturday, et al.
Science Advances (2022) Vol. 8, Iss. 46
Open Access | Times Cited: 41
Neeltje van Doremalen, Manmeet Singh, Taylor A. Saturday, et al.
Science Advances (2022) Vol. 8, Iss. 46
Open Access | Times Cited: 41
Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study
María‐Eugenia Zaballa, Javier Perez‐Saez, Carlos de Mestral, et al.
The Lancet Regional Health - Europe (2022) Vol. 24, pp. 100547-100547
Open Access | Times Cited: 41
María‐Eugenia Zaballa, Javier Perez‐Saez, Carlos de Mestral, et al.
The Lancet Regional Health - Europe (2022) Vol. 24, pp. 100547-100547
Open Access | Times Cited: 41
Spike protein of SARS‐CoV‐2 Omicron (B.1.1.529) variant has a reduced ability to induce the immune response
Cai He, Xuemei He, H. J. Yang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 39
Cai He, Xuemei He, H. J. Yang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 39
A Newly Engineered A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the Delta and Omicron Variants
Ching‐Wen Chang, Krishna Mohan Parsi, Mohan Somasundaran, et al.
Viruses (2022) Vol. 14, Iss. 7, pp. 1369-1369
Open Access | Times Cited: 39
Ching‐Wen Chang, Krishna Mohan Parsi, Mohan Somasundaran, et al.
Viruses (2022) Vol. 14, Iss. 7, pp. 1369-1369
Open Access | Times Cited: 39
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial
Rong Tang, Hui Zheng, Busen Wang, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 7, pp. 613-623
Open Access | Times Cited: 31
Rong Tang, Hui Zheng, Busen Wang, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 7, pp. 613-623
Open Access | Times Cited: 31
Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity
Alexander Muik, Bonny Gaby Lui, Jasmin Quandt, et al.
Cell Reports (2023) Vol. 42, Iss. 8, pp. 112888-112888
Open Access | Times Cited: 23
Alexander Muik, Bonny Gaby Lui, Jasmin Quandt, et al.
Cell Reports (2023) Vol. 42, Iss. 8, pp. 112888-112888
Open Access | Times Cited: 23
Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial
Pengfei Jin, Xiling Guo, Wei Chen, et al.
PLoS Medicine (2022) Vol. 19, Iss. 5, pp. e1003953-e1003953
Open Access | Times Cited: 34
Pengfei Jin, Xiling Guo, Wei Chen, et al.
PLoS Medicine (2022) Vol. 19, Iss. 5, pp. e1003953-e1003953
Open Access | Times Cited: 34
Prior Vaccination Exceeds Prior Infection in Eliciting Innate and Humoral Immune Responses in Omicron Infected Outpatients
Hye‐Kyung Lee, Ludwig Knabl, Mary Walter, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 30
Hye‐Kyung Lee, Ludwig Knabl, Mary Walter, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 30
Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques
Kyle Rosenke, Matt C. Lewis, Friederike Feldmann, et al.
JCI Insight (2022) Vol. 8, Iss. 4
Open Access | Times Cited: 30
Kyle Rosenke, Matt C. Lewis, Friederike Feldmann, et al.
JCI Insight (2022) Vol. 8, Iss. 4
Open Access | Times Cited: 30
Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study
Hong Zheng, Yunlong Cao, Xiaosu Chen, et al.
Cell Research (2022) Vol. 32, Iss. 8, pp. 781-784
Open Access | Times Cited: 29
Hong Zheng, Yunlong Cao, Xiaosu Chen, et al.
Cell Research (2022) Vol. 32, Iss. 8, pp. 781-784
Open Access | Times Cited: 29
Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice
Alexander Muik, Bonny Gaby Lui, Maren Bacher, et al.
Science Immunology (2022) Vol. 7, Iss. 78
Open Access | Times Cited: 28
Alexander Muik, Bonny Gaby Lui, Maren Bacher, et al.
Science Immunology (2022) Vol. 7, Iss. 78
Open Access | Times Cited: 28
Enhanced SARS-CoV-2 humoral immunity following breakthrough infection builds upon the preexisting memory B cell pool
Timm Weber, Sabrina Dähling, S. Rose, et al.
Science Immunology (2023) Vol. 8, Iss. 89
Closed Access | Times Cited: 19
Timm Weber, Sabrina Dähling, S. Rose, et al.
Science Immunology (2023) Vol. 8, Iss. 89
Closed Access | Times Cited: 19
